Molecule comparisons

Orforglipron Semaglutide

Both are now approved: one a weekly injection with a cardiovascular outcomes trial behind it, the other a once-daily pill whose case rests on access, not peak efficacy.

Orforglipron Tirzepatide

The widest efficacy gap in the incretin class set against the widest convenience gap: a dual agonist injection versus a once-daily tablet — both now approved.

CagriSema Tirzepatide

An approved dual incretin agonist against an investigational amylin plus GLP-1 combination; the reported magnitudes are close, the evidence maturity is not.

CagriSema Retatrutide

Two investigational obesity molecules at different stages: a Phase 3 amylin plus GLP-1 combination, and a Phase 2 triple agonist holding the larger number.

CagriSema Semaglutide

CagriSema is semaglutide with an amylin analog added in the same weekly shot; the question is whether the second pathway earns its place, and it is not approved.

Dulaglutide Liraglutide

Two first-generation GLP-1s that were compared directly in AWARD-6: once-weekly convenience against a slightly larger weight effect and an obesity indication.

Exenatide Liraglutide

The first GLP-1 ever approved against the one that displaced it. DURATION-6 compared them directly, and the result was not close.

Semaglutide Tesofensine

An approved drug with pivotal trials and a cardiovascular outcomes result against a single flagged Phase 2 number that was never confirmed. The evidence gap is the comparison.

Orforglipron Retatrutide

Two investigational molecules pulling in opposite directions: an oral small molecule chasing access, and an injectable triple agonist chasing maximum effect.

Amycretin Cagrilintide

Two Novo Nordisk amylin plays at opposite ends of the pipeline: one folds amylin and GLP-1 into a single molecule, the other is amylin alone.

Cagrilintide Semaglutide

Amylin against GLP-1, from the same company: one is the approved benchmark for weight loss, the other a different satiety hormone still proving it works alone.

Ecnoglutide Semaglutide

A cAMP-biased GLP-1 approved in China against the molecule that defined the class — same target, deliberately different signaling, very different regulatory reach.

Pemvidutide Survodutide

The two GLP-1/glucagon dual agonists, both investigational, chasing different prizes: one is optimizing body composition, the other has already read out Phase 3.

Survodutide Tirzepatide

Two different second hormones bolted onto GLP-1: tirzepatide adds GIP and is approved, survodutide adds glucagon and is investigational despite Phase 3 results.

Pemvidutide Tirzepatide

An approved GIP/GLP-1 with the largest weight-loss figure in the class against an investigational GLP-1/glucagon agonist competing on what the lost weight is made of.

CoQ10 MitoQ

Two mitochondria-targeted antioxidants with the same pitch and very different trial records — one has a positive heart-failure mortality trial, the other one positive vascular RCT and several recent nulls.

MitoQ SS-31

Two very different ways of protecting mitochondria — an antioxidant ferried into the organelle by charge, versus a peptide that binds the structural lipid cardiolipin directly — and only one has cleared an FDA approval.

Dietary nitrate (beetroot) Molecular hydrogen

Two antioxidant/vasodilator supplements sold for endurance and cardiovascular health, both with a real effect that shrinks or disappears once the user is well-trained.

Glutathione Molecular hydrogen

Two antioxidant supplements marketed for 'detox' and healthy aging — the body's own master antioxidant against a smaller, more selective free-radical scavenger — neither with outcome data beyond raising a biomarker.

Acetyl-L-carnitine Alpha-GPC

Two cholinergic-adjacent cognitive supplements with real dementia-population trial data — and the same gap between where they were studied and who actually buys them.

Acetyl-L-carnitine Alpha-lipoic acid

The two supplements most often stacked together for diabetic nerve pain — both real, both hitting the same ceiling: symptoms improve, the nerve itself does not.

Akkermansia muciniphila Lactoferrin

Two gut-focused supplements with real but narrow human trial support — one for the mucin barrier and metabolic markers, one mostly for tolerability rather than potency.

Akkermansia muciniphila Bovine colostrum

Two gut-barrier supplements that work by completely different routes — rebuilding the mucin layer versus delivering immunoglobulins under acute stress — with narrow, real evidence for each.

Acarbose Canagliflozin

Two approved diabetes drugs cleared the same NIA mouse longevity bar with the same male-only pattern — the choice between them, taken off-label for aging, comes down to side-effect profile, not the mouse data.

Canagliflozin Metformin

The two most talked-about 'off-label longevity' diabetes drugs — one has a human aging trial in progress that still hasn't reported, the other has only mouse data.

Berberine Canagliflozin

'Nature's Ozempic' against a real prescription SGLT2 drug with an actual, if mouse-only, longevity signal the OTC alternative doesn't have.

CoQ10 PQQ

Two mitochondrial-support supplements often stacked together — one with a positive heart-failure mortality trial, the other with a strong biogenesis mechanism and thinner human outcome data.

Ergothioneine Glutathione

Two antioxidants with a 'declines with age, so restore it' pitch — one a diet-derived amino acid with strong observational data and zero outcome trials, the other with a real trial showing supplementation raises the body's own stores.

Apigenin Luteolin

Two dietary flavonoids marketed on adjacent claims — sleep and NAD⁺ for one, mast-cell and neuroinflammation for the other — with the same underlying problem: almost no human trial data on the isolated compound itself.

Fisetin FOXO4-DRI

Two senolytics sold on striking mouse data — a flavonoid with one human trial that just reported null, and a peptide with a single landmark mouse study and no human trials at all.

Shilajit Tongkat Ali

Two herbal 'testosterone support' supplements with real small human trials behind them — a mineral-rich resin with a genuine contamination risk, and a root extract with the more consistent evidence base.

Alpha-GPC Phosphatidylserine

Two cholinergic/phospholipid nootropics with real but dated human trial data — one from dementia trials, the other from a form of the ingredient no longer actually sold.

Anastrozole Enclomiphene

Two prescription drugs used off-label by men to raise testosterone through completely different mechanisms — one blocks estrogen conversion, the other stimulates the brain's own signal to the testes.

Boron DHEA

Two mild hormone-adjacent supplements marketed for testosterone and vitality — a trace mineral that nudges free T via SHBG, and an adrenal prohormone that falls with age.

NAC (N-Acetylcysteine) TUDCA

Two supplements with genuine, specific medical pedigrees that get marketed as general 'liver support' and 'antioxidant' pills far beyond what they were proven for.

Humanin Klotho

Two 'longevity proteins' whose biology is genuinely compelling and whose supplement market is entirely aspirational — neither has a validated way to actually raise your own levels.

Berberine Dihydroberberine

Same glucose-lowering alkaloid, two forms — one with decades of human trial data, the other engineered for better absorption but with no outcome trials of its own.

Dietary nitrate (beetroot) L-citrulline

Two different routes to the same molecule, nitric oxide — one from the diet via oral bacteria, the other bypassing the gut's first-pass metabolism of arginine entirely.

Astaxanthin CoQ10

Two lipid-soluble antioxidants marketed for skin and 'anti-aging energy' — one with a real positive heart-failure mortality trial, the other with decent small skin-photoaging data and little else.

Cordyceps Rhodiola Rosea

Two adaptogenic supplements sold for energy and stress resilience — one with modest aerobic gains only in untrained people, the other with a real but short-term stress-fatigue signal.

Citicoline Huperzine A

Two cholinergic nootropics sold for memory and focus — a choline-donor prescription drug abroad whose largest placebo-controlled trials failed, against a microgram-dosed acetylcholinesterase inhibitor that's pharmacologically a drug wearing a supplement label.

Creatine HMB

The best-evidenced supplement on this entire site against a purpose-built anti-catabolic — one for building strength and lean mass, the other specifically for not losing it.

Berberine Inositol

Two metabolic supplements that overlap heavily in the PCOS/insulin-resistance conversation — one with a wider glucose/lipid trial base, the other with the more PCOS-specific evidence.

Akkermansia muciniphila Butyrate

Two gut-barrier compounds with completely different mechanisms — one a bacterium that rebuilds the mucin layer, the other the colonocyte's own preferred fuel — and the same open question: does a capsule actually deliver either where it needs to act.

Mazdutide Tirzepatide

An approved-in-China dual agonist against the most effective FDA-approved weight-management drug available — real efficacy data on both sides, but very different regulatory maturity.

Gonadorelin Kisspeptin

Two peptides sitting at different points of the same reproductive axis — one an approved diagnostic drug being repurposed off-label, the other a hormone with real biology and zero approved products.

Epitalon SS-31

Two 'anti-aging peptides' with almost opposite evidence problems — one built on decades-old, unreplicated Russian research, the other with a real (if narrow) FDA approval its marketing rarely mentions.

Curcumin Sulforaphane

Two plant-derived anti-inflammatory compounds with a shared problem — real cell-biology mechanisms undermined by how badly the body actually absorbs them.

Magnesium L-Threonate Phosphatidylserine

Two 'brain-specific' cognitive supplements whose entire human evidence case rests on a single small, often industry-linked trial each.

ARA-290 VIP (Vasoactive Intestinal Peptide)

Two investigational cytoprotective/anti-inflammatory peptides with a shared pattern — a real, narrow positive signal in one specific condition, followed by disappointing results everywhere else.

Larazotide LL-37

Two peptides sold for gut/barrier health with genuinely different regulatory maturity — one that actually reached Phase 3 and failed, the other still entirely preclinical.

KPV Thymosin α1

Two immune-modulating peptides at very different evidence stages — one an approved drug in dozens of countries for serious infection, the other a mouse-only anti-inflammatory fragment.

Enclomiphene Gonadorelin

Two ways to raise a man's own testosterone while preserving fertility — one restarts the brain's pulsatile signal directly, the other blocks estrogen's feedback on that same signal.

5-Amino-1MQ SLU-PP-332

Two novel small-molecule 'metabolism in a pill' compounds with elegant mouse mechanisms and the exact same problem — zero human trials of any kind.

Akkermansia muciniphila Larazotide

Two gut-barrier approaches on completely different routes — a bacterium that rebuilds the mucin layer with a mixed but genuinely positive human RCT record, and a synthetic tight-junction regulator that failed its pivotal trial.

Cardarine SLU-PP-332

Two 'exercise in a pill' compounds discontinued or unapproved for very different reasons — one a real PPARδ agonist GSK abandoned over cancer findings, the other a brand-new synthetic never tested in a person.

Icariin Melanotan II

Two libido-adjacent products with opposite risk profiles — a weak herbal PDE5 inhibitor with essentially no human trial data, against an unapproved gray-market injectable with a documented harm record.

Rhodiola Rosea Selank

Two anxiety/stress compounds from very different traditions — a synthetic Russian anxiolytic peptide claimed to match benzodiazepines, against an adaptogenic root with a genuine, if modest, placebo-controlled trial record.

DSIP Glycine

Two 'sleep' compounds separated by five decades of research maturity — a 1970s peptide whose own receptor was never confirmed, against a cheap amino acid with real modern sleep-quality trial data.

CJC-1295 Sermorelin

Both are GHRH analogs acting on the same receptor. The real difference is regulatory: sermorelin has a pediatric clinical record and a compounding route; CJC-1295 is research-only.

GHRP-2 Ipamorelin

Two ghrelin-receptor secretagogues separated by selectivity. GHRP-2 pulls cortisol, prolactin and appetite along with the GH pulse; ipamorelin was engineered to leave those alone.

GHRP-6 Ipamorelin

Same receptor, opposite design intent. GHRP-6 is the blunt first-generation tool whose hallmark is hunger; ipamorelin was engineered to release GH with minimal spillover.

GHRP-2 GHRP-6

Two first-generation ghrelin-receptor peptides. GHRP-2 is the more characterized and more aggressive releaser; GHRP-6 is the one defined by how hungry it makes you.

GHRP-1 GHRP-6

The prototype versus the one that actually got studied. Both are early ghrelin-receptor peptides; GHRP-6 has far more human pharmacology and a defining appetite effect.

GHRP-6 Hexarelin

Potency versus appetite. Hexarelin is among the strongest GH-releasing peptides ever put into people; GHRP-6 is the milder relative whose hallmark is hunger. Neither is selective.

Ipamorelin MK-677

An injectable selective peptide against an oral small molecule. MK-677 has by far the deeper trial record, and that record is largely what argues against it.

CJC-1295 MK-677

Different levers on the same axis: CJC-1295 is a long-acting GHRH analog, MK-677 an oral ghrelin mimetic. Only one has been taken to outcome trials.

IGF-1 DES(1,3) IGF-1 LR3

Two IGF-1 analogs engineered to slip past the same binding-protein brake, one by subtracting mass and one by adding it; the real difference is duration, not evidence.

IGF-1 LR3 Mechano Growth Factor (MGF)

Both trade on IGF-1 biology in muscle, but one is a long-acting laboratory reagent and the other is a load-induced splice variant your own muscle already makes.

AOD-9604 HGH Fragment 176-191

Two forms of the same growth-hormone tail. One was developed into a named obesity drug candidate and tested in people; the other inherited the marketing without the trial record.

CJC-1295 Tesamorelin

Both are GHRH analogs that prompt the pituitary to release its own growth hormone. Only one is FDA-approved, and only for a narrow, specific indication.

Follistatin Mechano Growth Factor (MGF)

Two elegant muscle-growth mechanisms whose most impressive data belong to gene therapy and to your own genes, not to the injectable vials sold under their names.

GHRP-2 Sermorelin

Two different doors to the same growth-hormone pulse, a ghrelin-receptor agonist versus a GHRH analog. The gap that matters is selectivity and regulatory standing.

GHRP-2 Hexarelin

Close cousins at the ghrelin receptor: one is more potent, one has a defined diagnostic role, and both drag cortisol along and fade with repeated dosing.

BPC-157 GHK-Cu

One is an injected research peptide with no human trials; the other is a copper tripeptide whose usable human evidence is topical and cosmetic. Route decides almost everything.

GHK-Cu TB-500

Both are sold as repair peptides, but each one's only real human data sits somewhere narrow and unrelated: a cosmetic cream for one, a dry-eye drop for the other.

BPC-157 Pentadeca Arginate

The same fifteen-amino-acid healing pitch twice: one molecule with a deep rodent literature behind it, and one with a near-empty file of its own.

Pentadeca Arginate TB-500

A rebranded BPC-157 salt with almost no literature of its own, against a peptide whose single randomized human result is about an eye drop.

GHK-Cu Matrixyl

Two topical peptides aimed at the same cell, the fibroblast, with plausible mechanisms, small effect sizes, and a shared dependence on whether anything crosses the skin barrier.

Argireline Matrixyl

Same shelf, opposite mechanisms: one tries to quiet the muscle that folds the skin, the other tries to tell fibroblasts to rebuild what folding wore away.

Collagen Peptides GHK-Cu

An oral supplement with placebo-controlled trials and a pooled analysis behind it, against a topical copper peptide whose human data stop at small cosmetic studies.

Selank Semax

Two Russian heptapeptides out of the same research tradition, split by target: Selank was studied for anxiety, Semax for stroke and cognition. Neither has Western trial data.

Noopept Semax

Both are Russian-registered nootropics that raise neurotrophins in animals, but one is an oral dipeptide and the other an intranasal ACTH fragment. Neither is FDA-approved.

Noopept Selank

Same Russian pharmacology tradition, different jobs: Noopept was developed for cognition, Selank as an anxiolytic. Both have human data that stops well short of Western standards.

Dihexa Semax

Not a close call but a real evidence gap: Semax has small human studies behind it, Dihexa has none, plus a growth-pathway mechanism nobody has cleared in people.

DSIP Selank

Sleep versus anxiety, and two very different depths of evidence: Selank has small human anxiety trials, while DSIP's basic biology is still unsettled after nearly fifty years.

Dihexa P21

Two preclinical nootropic peptides with no human trials at all. The only real difference is which unanswered question is bigger: safety, or what is actually in the vial.

Oxytocin PT-141

One is FDA-approved for a single narrow sexual-desire indication; the other is a famous hormone whose most-cited behavioral findings largely failed to replicate.

Kisspeptin PT-141

Both have been studied in hypoactive sexual desire disorder, but only one cleared the FDA. Kisspeptin remains an early-phase research tool with no approved use.

Melanotan II PT-141

Same melanocortin mechanism, opposite regulatory standing: bremelanotide cleared phase 3 for one narrow indication, while Melanotan II never entered that system at all.

Kisspeptin Oxytocin

Two genuine human hormones with real academic literatures and two different failure modes: oxytocin's famous findings did not replicate, and kisspeptin's research never reached late stage.

MOTS-c SS-31

Both aim at the mitochondrion, but only one has been through randomized human trials, and SS-31's record is mostly misses while MOTS-c has never been tested in people.

Humanin MOTS-c

The two founding mitochondrial-derived peptides, graded the same way. Humanin's preclinical work is cytoprotective and neuronal; MOTS-c's is metabolic and muscular. Neither has human outcome trials.

Epitalon MOTS-c

Both are sold as longevity injectables with no approval, but they fail different tests: MOTS-c has credible science and no human trials, epitalon has human claims nobody has replicated.

Humanin SS-31

Humanin has never been through a randomized human trial; SS-31 has been through several and mostly missed their endpoints. Two different ways of not being proven.

BPC-157 KPV

Two healing peptides with deep rodent literatures and no controlled human trials. The real difference is scope: BPC-157 spans tissue repair broadly, KPV is anti-inflammatory and gut-focused.

Thymalin Thymosin α1

Two thymus peptides sold for immunity and longevity, separated by evidence quality: thymosin alpha-1 is an approved drug in dozens of countries, thymalin rests on one unreplicated program.

KPV LL-37

Both are natural human immune peptides with no controlled human trials, but they push in opposite directions: KPV dampens inflammatory signaling, LL-37 can drive it.

KPV Larazotide

Two gut peptides at opposite ends of the pipeline: KPV has never been tried in humans, larazotide was tried in celiac disease and its pivotal Phase 3 failed.

5-Amino-1MQ Adipotide

Two fat-loss compounds that never reached approved human use. One has a clean mechanism and no data in people at all; the other has a dramatic primate result and a kidney-toxicity signal.

ARA-290 BPC-157

Both are sold as repair peptides, but only ARA-290 has randomized human data behind it. BPC-157's entire case is rodent, and neither molecule is approved.

Ashwagandha Tongkat Ali

Two botanicals sold as natural testosterone, both strongest on stress. The split is how deeply the trials replicate, and how closely the bottle you buy resembles what was studied.

Ashwagandha Rhodiola Rosea

Two adaptogens with genuinely different jobs: calming an over-revved stress response, versus holding mental performance together when you are already depleted.

Fadogia Agrestis Tongkat Ali

The famous podcast stack, pulled apart. One half has small human randomized trials; the other has rat studies that recorded organ damage alongside the testosterone rise.

Ashwagandha Turkesterone

An adaptogen with replicated placebo-controlled trials against a natural anabolic whose entire human record is one small acute study that found nothing significant.

DHEA Testosterone (TRT)

A prescription hormone therapy gated behind a diagnosis, against an over-the-counter prohormone whose real evidence sits in true deficiency, not in aging or low testosterone.

Creatine Turkesterone

The most-studied supplement in this aisle against the least, with one clarification: creatine's human evidence is about training output, not hormones.

NAD⁺ IV therapy NAD⁺ precursors

Same molecule, two delivery routes. One has randomized human data for raising NAD+; the other is a clinic infusion at $250 to $1,500 a session with no controlled outcome trial.

NAD⁺ precursors Urolithin A

Both are sold for cellular energy, but only one has placebo-controlled trials measuring something a person might feel. NAD+ precursors move a biomarker; urolithin A moved muscle endurance.

Glutathione NAC (N-Acetylcysteine)

Swallow the antioxidant itself, or the precursor that lets you build it. Oral glutathione raises body stores; NAC's real credentials are medical, not the daily antioxidant capsule.

GlyNAC NAC (N-Acetylcysteine)

Not rival products: GlyNAC is NAC plus glycine, the second amino acid glutathione is built from. The real question is whether adding glycine buys you anything.

Methylene blue NAD⁺ precursors

Two approaches to mitochondrial energy with very different risk profiles: an approved drug repackaged as a biohack, versus a supplement that reliably moves a biomarker and nothing more.

Cordyceps Lion's Mane

Two mushrooms aimed at two different jobs, aerobic capacity versus cognition. Both rest on small, short human trials and mechanisms that still live mostly in the lab.

Lion's Mane Rhodiola Rosea

Both are sold for the brain, but for different failure modes: adding cognitive function versus keeping it from sagging when you are stressed, run down and short on sleep.

Fisetin Quercetin

Two flavonoids with senolytic reputations neither has earned in humans. Fisetin's case is entirely in mice; quercetin's belongs to a drug combination, not to quercetin alone.

Fisetin Spermidine

Two preclinical favorites with the same shape of problem. Excellent mouse data on both sides, and human evidence that is either not yet in or, for spermidine, already negative.

Pterostilbene Resveratrol

Nearly the same molecule, with one real difference: pterostilbene is far better absorbed. What neither has is human evidence that the absorption buys anything on aging.

Metformin Rapamycin

Two prescription drugs borrowed for longevity from opposite ends of biology: an old, cheap diabetes tablet versus a transplant immunosuppressant with the field's best animal lifespan data.

Creatine Taurine

One has hundreds of human trials behind its core claim; the other has a mouse lifespan result and a human premise a 2025 analysis failed to replicate.

Calcium AKG Spermidine

Both are preclinical stories with a striking human number attached, and in both cases the number comes from a study design that cannot carry it.

LGD-4033 RAD-140

Both are unapproved and prohibited in sport at all times. The only real difference between them is how much has actually been measured, and in whom.

LGD-4033 Ostarine

The two SARMs with genuine human trials, asking different questions: three weeks of dosing in healthy men, against two completed phase 3 programs in patients.

Ostarine RAD-140

One was taken through two phase 3 trials and failed the endpoint that mattered. The other has never been tested for muscle in anyone, at any dose, in any phase.

LGD-4033 Turkesterone

The natural-alternative framing, checked from both sides: an unapproved SARM with measured human numbers, against an ecdysteroid whose one human study found nothing.

Cardarine Ostarine

Sold side by side and constantly confused. Cardarine is not a SARM at all — different receptor, different class, and a completely different reason it never became a drug.

Bimagrumab Ostarine

A monoclonal antibody and a SARM, both of which reliably add lean mass on a scan, and neither of which has ever improved what that mass is supposed to do.

Alpha-lipoic acid Benfotiamine

The two supplements with real randomized programs in diabetic peripheral neuropathy, different mechanisms, and the same ceiling: symptom scores move, the nerve does not.

Fisetin Luteolin

Both reach the senolytic shelf from different chemistry: a flavonol that topped the screen the whole idea came from, and a flavone that barely registered in it.

Luteolin Quercetin

One hydroxyl apart — a flavone and a flavonol — and routinely treated as the same thing. Their human records are the part that does not match.

Glycine Taurine

Two cheap amino acids, each carrying an animal lifespan result and a human story that does not follow from it. The limits are different, and they matter.

Curcumin Low-dose naltrexone

Both get reached for in chronic pain and inflammation: an over-the-counter botanical that barely absorbs, and a compounded prescription whose best trial came back null.

Cistanche Tongkat Ali

Two herbs sold on the same promise — more testosterone, more vitality. Only one has a trial that measured testosterone at all.

Beta-glucan Fucoidan

Two polysaccharides sold for immunity — one from oats or yeast, one from seaweed. The strongest evidence belongs to the form almost nobody buys for immunity.

Exosome therapy GHK-Cu

Two regenerative pitches for skin and hair: a copper peptide with real biology in a dish, and a clinic procedure the FDA has issued safety reports about.

Astragalus (TA-65) Fisetin

Two longevity supplements, two different mechanisms — lengthen the telomere, or clear the senescent cell. Both are sold well ahead of their evidence.

Berberine Beta-glucan

Two supplements aimed at the same metabolic panel — one at glucose and lipids together, one at LDL alone. Only one carries an authorized claim.

Cerebrolysin Citicoline

Two compounds given for stroke and cognitive decline, both with real trials — and both with a null result sitting at the center of the record.

Gotu kola Lion's Mane

Both are sold for memory. One's randomized evidence is about leg veins; the other's is small, short, and at least about the brain.

Lithium orotate Magnesium L-Threonate

Two minerals sold in a special salt for the brain. In both cases the salt is the marketing and the evidence sits somewhere else.

Melanotan I (Afamelanotide) PT-141

Two melanocortin drugs that genuinely won FDA approval — one for a rare light sensitivity, one for low desire — and are sold online as neither.

Dietary nitrate (beetroot) Nattokinase

Two supplements aimed at blood pressure and blood flow. One has a mapped mechanism and a measurable effect; the other carries a bleeding risk.

Oral semaglutide Orforglipron

The two GLP-1s you can swallow. One is a peptide with food and water rules, the other a small molecule with none — and their records are not the same size.

Paraxanthine Rhodiola Rosea

Two routes to feeling less tired: caffeine's own metabolite sold as a smoother stimulant, and an adaptogen sold for stress-related fatigue.

Bovine colostrum Lactoferrin

Not really two products: one is a fraction of the other, sold separately at a declared dose — and the whole-food version almost never says how much of it you are getting.

Bovine colostrum Collagen Peptides

Two protein powders sold for everything, separated by one unglamorous fact: only one of them is usually sold at the dose its trials used.

Ashwagandha Kanna

Two herbs sold for the same feeling, with completely different risk profiles — one works on cortisol, the other on the serotonin transporter.

DHEA Pregnenolone

One step apart on the same steroid pathway — and that one step is the difference between a compound with real trials and a compound with a marketing story.

Milk thistle TUDCA

The two great liver supplements, and the same lesson twice: the evidence people quote for each belongs to something you are not actually buying.